MENU
DNTH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Dianthus Therapeutics (DNTH) Ownership - Who owns Dianthus Therapeutics?
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies... Show more
Profile
Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
595.6M
P/E Ratio
3.24
Total Cash
275.24M
Projected Growth
N/A
Total Debt
1.49M
Revenue
6.24M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
8.56
Total Debt/Equity
N/A
Revenue/Share
0.18 USD as % of share price
Fundamentals
DNTH
Capitalization
596M
P/E Ratio
3.24
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
275M
Total Cash/Share
8.56
Total Debt
1.49M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.18%
Revenue
6.24M
ROE
N/A
Book Value
352M
P/B Ratio
1.81
Cash Flow
N/A
Earnings
-2.55
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
31K
Current Ratio
15.22
Current Revenue Per Employee
17000.00
Dividends Per Share - Security
N/A
EBITDA
-101.45M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-30.71
Shares Held By Institutions
952M
Shares Outstanding - Current
32.2M
Total Liabilities
21.5M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-18.899
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com